Hybrid oligomers, their preparation process and pharmaceutical compositions containing them
View Patent ↗The present invention relates to compositions and methods for producing therapeutic oligomeric compounds. In one aspect the invention relates to methods for administering the oligomeric compounds for the treatment and prevention of disease, for example, a fungal infection, bacterial infection, or cancer, in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, pharmacologically active agent or a combination thereof.
1. An oligomeric compound of formula I:
wherein i is an integer varying from 7 to 9;
wherein R a is a member independently selected from the group consisting of a hydrogen atom, an amino acid side chain, a (C 1 -C 10 ) alkyl, and (C 1 -C 10 ) bicyclic heteroaryl group comprising up to 5 N groups optionally substituted by 1 to 6 substituents further selected from the group consisting of: amidine, (C 1 -C 10 ) alkyl, or NH 2 ,
wherein Z a is CH 2 or NH;
wherein X is selected from the group consisting of a
wherein Y represents NH 2 , or a group chosen among the following:
2. The oligomeric compounds of claim 1 , wherein at least 30% to 50% of the groups R a comprise
3. The oligomeric compound of claim 1 , wherein i=8.
4. The oligomeric compound of claim 1 , wherein said compound is present in combination with a pharmaceutically acceptable excipient.
5. The oligomeric compound of claim 4 , wherein the combination comprises a per unit dose of from about 10 to about 2000 mg of a compound of claim 1 .
6. A pharmaceutical compound comprising the oligomeric compound of claim 1 conjugated to a pharmacologically active molecule.
7. The pharmaceutical compound of claim 6 , wherein the pharmacologically active molecule is conjugated to a terminus of the oligomeric compound.
8. A medicament for the treatment of bacterial, or fungal diseases, and in particular fungal infections such as aspergillosis and candidosis, and resistant bacterial infections comprising an effective amount of the oligomeric compound of claim 1 .
9. The oligomeric compound of claim 1 , wherein i=7.
10. The oligomeric compound of claim 1 , wherein i=9.
11. The ologomeric compound of claim 1 , wherein R a is a member selected from the group consisting of a
12. The oligomeric compound of claim 1 , wherein i=7 and Z a is NH.
13. The oligomeric compound of claim 1 , wherein i=8 and Z a is CH 2 .
14. The oligomeric compound of claim 1 , wherein i=9 and Z a is NH.
15. The oligomeric compound of claim 1 , having the formula of Mol-1:
16. The oligomeric compound of claim 1 , having the formula of Mol-2:
17. The oligomeric compound of claim 1 , having the formula Mol-3:
18. The oligomeric compound of claim 1 , having the formula Mol-4:
19. The oligomeric compound of claim 1 , having the formula Mol-5:
20. The oligomeric compound of claim 1 , having the formula Mol-6:
21. The oligomeric compound of claim 1 , having the formula Mol-7:
22. The oligomeric compound of claim 1 , having the formula of Mol-8:
23. A method for the treatment of disease in an individual comprising:
providing a composition comprising the oligomeric compound of claim 1 and a pharmaceutically acceptable carrier, and administering an effective amount of said oligomeric compound in a pharmaceutically acceptable form to an individual, wherein the individual suffers from a fungal infection, bacterial infection, or a combination thereof.
24. The method of claim 23 , wherein the fungal infection comprises aspergillosis and candidosis.
25. A process for the preparation of an oligomeric compounds of claim 1 , comprising:
(a) preactivating monomers of formula GP-D-W, wherein GP is a protective group selected from the group consisting of Fmoc, Teoc, phtalimide, Alloc, BOC and Cbz; D is
wherein R a and Z a are as defined in claim 1 , W is OH or is a member selected from the W-H group consisting of N-hydroxysuccinimide, phenol, pentafluorophenol, pentachlorophenol, p-nitrophenol, 2,4-dinitrophenol, 2,4,5-trichlorophenol, 2,4-dichloro-6-nitrophenol, hydroxy-1,2,3,-benzotriazole, 1-oxo-2-hydroxydihydrobenzo-triazine (HODhbt), 7-aza-1-hydroxy-benzotriazole (HOAt), 4-aza-1-hydroxybenzo-triazole (4-HOAt), imidazole, tetrazole, and WANG resin;
(b) coupling of GP-D-W as defined above on an amine function of a support, wherein the coupling allows the grafting of the -D-GP group to said amine function of said support;
(c) cleaving of the GP group;
(d) repeating of steps (a) and (b) until n D groups have been added to the grafted group(s), wherein the new -D-GP group(s) is added to the previously grafted group(s), wherein n is as defined in claim 1 ,
(e) adding the X group as defined in claim 1 to the grafted groups; and
(f) cleaving of the compound of formula (I) from the support, which allows the removal of the resin and the release of the Y group, as defined in claim 1 .
26. The process of claim 25 , wherein step (b) is carried out in the presence of a tertiary base selected from the group consisting of DIEA, collidine, NMM and lutidine; and in the presence of a catalyst.
27. The process of claim 26 , wherein said catalyst is HOBt.
28. The process of claim 25 , wherein step (b) is carried out in a solvent selected from the group consisting of DMF, CH 2 Cl 2 , THF, and N-methylpyrrolidone.